products

Dronedarone hydrochloride CAS 141625-93-6 Pharmaceutical Grade Chemicals

Basic Information
Place of Origin: CHINA
Brand Name: MOSINTER
Certification: COA
Model Number: Circulatory System Drugs API - 3
Minimum Order Quantity: 1KG
Price: Negotiation
Packaging Details: Aluminum foil bag , kraft paper bag
Delivery Time: Within 7 days
Payment Terms: L/C, T/T
Supply Ability: Can be customized according to customer requirements
Detail Information
Name: Dronedarone Hydrochloride CAS: 141625-93-6
Form: Powder Molecular Formula: C31H44N2O5S.ClH
Molecular Weight: 593.224 Color: White
High Light:

chemical raw materials

,

raw material for medicine manufacturing


Product Description

Dronedarone hydrochloride CAS 141625-93-6 Pharmaceutical Grade Chemicals
 
Description:
 

Product Name:

Dronedarone Hydrochloride

Synonyms:

Dronedarone HCl;Dronedarone hydrochloride(SR33589B);MethanesulfonaMide,N-[2-butyl-3-[4-[3-(dibutylaMino)propoxy]benz;MethanesulfonaMide,N-[2-butyl-3-[4-[3-(dibutylaMino)propoxy]benzoyl]-5-benzofuranyl]-,hydrochloride (1:1);N-(2-Butyl-3-(4-(3-(dibutylaMino)propoxy)benzoyl)benzofuran-5-yl)MethanesulfonaMide hydrochloride;N-[2-Butyl-3-[4-[3-(dibutylaMino)propoxy]benzoyl]-5-benzofuranyl]MethanesulfonaMide Hydrochloride

CAS:

141625-93-6

MF:

C31H44N2O5S.ClH

MW:

593.224


Specifications:
 

Description

White powder

Complies

Identification

IR

Complies

 

HPLC

Complies

Heavy metal

≤10ppm

5ppm

Pb

≤3ppm

1.5ppm

Hg

≤0.1ppm

0.05ppm

Cd

≤1ppm

0.2ppm

Loss on drying

≤0.5%

0.12

Residue on lgnition

≤0.1%

0.03

Single impurity

≤0.5%

0.12

Total impurity

≤1.0%

0.29

Total bacteria

≤1000cfu/g

<1000

Yeast and Mould

≤100 cfu/g

<000

E.coli/25g

Absent

Absent

Salmonella/25g

Absent

Absent

Assay

≥99.0%

99.4%

Conclusion

Conforms with USP/EP standards


Application: 
 

Dronedarone has been termed a "multichannel blocker" however it is unclear which channel(s) play a pivotal role in its success. Thus, dronedarone's actions at the cellular level are controversial with most studies suggesting an inhibition in multiple inward potassium currents including rapid delayed rectifier, slow delayed rectifier and ACh-activated inward rectifier.[7] It is also believed to reduce inward rapid Na current and L-type Ca channels. The reduction in K current in some studies was shown to be due to the inhibition of K-ACh channel or associated GTP-binding proteins. Reduction of K+ current by 69% led to increased AP duration and increased effective refractory periods, thus shown to suppress pacemaker potential of the SA node and return patients to a normal heart rhythm. In a European trial, the average time to recurrence of an arrhythmia was 41 days in the placebo group vs. 96 days in the dronedarone group (similar results obtained in the non-European trial, 59 and 158 days respectively).


Our strengths:
 
We can customize according to customer's requirement.
If you have any question pls mail us or call us.
 

 

 

Contact Details
Fedor

Phone Number : +86 18989305995

WhatsApp : +18989305995